Quetiapine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "alpha" to "α") |
Elcatracho (talk | contribs) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 46: | Line 46: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Mechanism not well understood | *Mechanism not well understood | ||
*Antagonizes D2, 5HT, histamine H1, and | *Antagonizes D2, 5HT, histamine H1, and α<sub>1</sub> receptors, as well as muscarinic and norepinepherine receptors. | ||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[Antipsychotics]] | *[[Antipsychotics]] | ||
*[[Antipsychotic toxicity]] | |||
*[[Extrapyramidal reaction]] | *[[Extrapyramidal reaction]] | ||
*[[QT prolongation]] | *[[QT prolongation]] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Psychiatry]] | |||
Latest revision as of 04:09, 7 March 2021
Administration
- Type: Atypical antipsychotics
- Dosage Forms: ER, IR
- Routes of Administration: oral
- Common Trade Names: Seroquel
Adult Dosing
- 25-400 mg PO 1-2 times daily
Pediatric Dosing
Safety/efficacy not established in children <10 years old
- 25-400 mg PO 1-2 times daily
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal: No adjustment
- Hepatic dosing: initial dose 25 mg/day, titrate up slowly
- Concomitant use with strong CYP3A4 inducer: may need increased dose
- Concomitant use with strong CYP3A4 inhibitor: reduce quetiapine dose
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Prolonged QT interval, sudden cardiac death, syncope
- Neuroleptic malignant syndrome, tardive dyskinesia
- DKA
- Agranulocytosis, neutropenia
- Seizure
- Pancreatitis
- Suicidal ideation
Common
- Hypertension, weight gain, hyperlipidemia
- Abdominal pain, constipation, nausea/vomiting, xerostomia
- Somnolence, dizziness, asthenia, tremor, insomnia
- Extrapyramidal disease
- Headache
- URI-like symptoms
Pharmacology
- Half-life: 6-7 hours
- Metabolism: hepatic, extensive via CYP3A4
- Excretion: mostly renal
Mechanism of Action
- Mechanism not well understood
- Antagonizes D2, 5HT, histamine H1, and α1 receptors, as well as muscarinic and norepinepherine receptors.